Viromed Medical AG, a medical technology company and pioneer in cold plasma technology, announced the successful completion of a multi-year research study on the application of cold atmospheric plasma (CAP) in the lung. The study data will now be submitted for publication in a renowned scientific journal.
The research focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine. Results confirm the potential of cold plasma as a physical, non-pharmacological treatment for severe infectious lung diseases. The data demonstrate a clearly defined therapeutic safety window and complete reduction of pathogenic germs in lung epithelial models.
A key component was ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School. The isolated, ventilation- and perfusion-capable lung model realistically reflects key physiological characteristics of the human lung, enabling reproducible investigations on vital organ tissue.
Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated: "By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems. It is particularly encouraging that we are already seeing first successful applications in patients in a university clinical setting."
Based on the study results, Viromed's technology was used in a university setting for a severe pulmonary individual case in a human patient. Following ethics committee approval, a university hospital with a lung and transplantation medicine department treated a patient with massive complications after a lung transplant. The use of cold plasma was very successful, and the treating physicians noted an exceptional positive clinical course. The hospital plans to publish the case soon, and further severely ill patients with high risk of fatal outcome are undergoing treatment.
Viromed sees clear indications that cold plasma technology will fundamentally change pneumology. While classical pharmacological therapies are increasingly limited by resistance development, cold plasma as a physical mode of action opens a new therapeutic dimension, including prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research, such as intracardiac use for bacterial endocarditis or application in the thorax for bacterial pleural empyema.
More information about Viromed Medical AG is available at www.viromed-medical-ag.de. The original release can be viewed on www.newmediawire.com.
